4D Molecular Therapeutics $FDMT
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS9
PHASE 3 / 2-33
RECRUITING5
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO71%
Delay Index: of 7 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →
Open 4D Molecular Therapeutics on the live radar map → 📅 $FDMT readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| 4D-310 NCT04519749 |
P1/2 | Active, not recruiting | Fabry Disease | 18 | 2026-01 |
| 4D-125 IVT Injection NCT04517149 |
P1/2 | Active, not recruiting | X-Linked Retinitis Pigmentosa | 21 | 2026-06 (+39 mo) |
| 4D-310 NCT05629559 |
P1/2 | Recruiting | Fabry Disease | 18 | 2026-06 (+24 mo) |
| 4D-150 IVT NCT05197270 |
P1/2 | Recruiting | Neovascular (Wet) Age-Related Macular Degeneration | 215 | 2027-03 (+9 mo) |
| 4D-150 IVT (3E10 vg/eye) NCT06864988 |
P3 | Active, not recruiting | Macular Neovascularization Secondary to Age-Related Macular Degeneration | 480 | 2027-06 |
| CF NCT05248230 |
P2 | Recruiting | Cystic Fibrosis Lung | 30 | 2027-06 (+34 mo) |
| 4FRONT-2 NCT07064759 |
P3 | Recruiting | Neovascular Age-Related Macular Degeneration (nAMD) | 480 | 2027-11 (-12 mo) |
| 4SIGHT NCT07867080 |
P3 | Recruiting | Diabetic Macular Edema (DME) | 514 | 2029-01 |
| 4D-150 IVT NCT05930561 |
P2 | Active, not recruiting | Diabetic Macular Edema; Diabetic Retinopathy | 72 | 2029-02-28 (+12 mo) |